Fabrice Jean Denis Pierre

This inventor holds 12 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fabrice Jean Denis Pierre. Retrieved from https://idiyas.com/inventor/fabrice-jean-denis-pierre

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 22.0

ph-index = 6

Forward Citations = 152(Granted Patents)

Company Filing History:

12 out of 1,168

Vertex Pharmaceuticals, Inc.

patents

Years Active: 2017-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12384762 - Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2025-08-12),

2. 12168009 - Modulators of cystic fibrosis transmembrane conductance regulator (2024-12-17),

3. 11453655 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2022-09-27),

4. 11426407 - Modulators of cystic fibrosis transmembrane conductance regulator (2022-08-30),

5. 11414439 - Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2022-08-16),

6. 11186566 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2021-11-30),

7. 10793547 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-10-06),

8. 10758534 - Modulators of cystic fibrosis transmembrane conductance regulator (2020-09-01),

9. 10570115 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-02-25),

10. 10258624 - Modulators of cystic fibrosis transmembrane conductance regulator (2019-04-16),

11. 10233191 - Fused piperidine amides as modulators of ion channels (2019-03-19),

12. 9782408 - Modulators of cystic fibrosis transmembrane conductance regulator (2017-10-10),

Title: Innovations by Fabrice Jean Denis Pierre

Introduction

Fabrice Jean Denis Pierre is a prominent inventor based in La Jolla, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the treatment of cystic fibrosis. With a total of 12 patents to his name, Pierre's work has the potential to impact the lives of many patients suffering from this genetic disorder.

Latest Patents

Among his latest patents is a modulator of the Cystic Fibrosis Transmembrane Conductance Regulator. This invention includes pharmaceutical compositions, methods of treatment, and processes for making the modulator. The compounds disclosed in his patents include pharmaceutically acceptable salts, deuterated derivatives, and metabolites. Additionally, he has developed solid-state forms of these compounds, which are crucial for effective treatment options for cystic fibrosis.

Career Highlights

Fabrice Jean Denis Pierre is currently associated with Vertex Pharmaceuticals, Inc., a leading company in the biotechnology sector. His work focuses on developing innovative therapies that target CFTR-mediated diseases, including cystic fibrosis. His extensive research and development efforts have positioned him as a key figure in the pharmaceutical industry.

Collaborations

Pierre has collaborated with notable colleagues such as Jinglan Zhou and Mark Thomas Miller. These partnerships have enhanced the scope and impact of his research, leading to advancements in the treatment of cystic fibrosis.

Conclusion

Fabrice Jean Denis Pierre's contributions to pharmaceutical innovation are noteworthy. His patents and ongoing research continue to pave the way for new treatments that can significantly improve the quality of life for individuals with cystic fibrosis.

Profile summary based on public USPTO records.